Abstract
NR2B antagonists have received considerable attention in recent years. In this class of excitatory amino acid receptor antagonists NR2B antagonists have shown efficacy in neuroprotection, anti-hyperalgesic and anti-Parkinson animal models. Several groups are involved in developing these compounds as therapeutic agents and evaluating newer therapeutic targets for these agents. Until recently benzylpiperidine and phenylpiperidine templates, which were based on the structures of Ifenprodil and Eliprodil, formed the basis of most SAR in this area. A few chemical leads in this class such as CP-101,606, Ro25,6981 and PD0196860 have been identified as possible development leads which have generated significant interest in this area. In addition to the efforts of Pfizer (Parke-Davis), Roche and E.Merck, several other industrial and academic research groups have continued to work in the NR2B area and recently Merck and Roche have reported new chemical leads as NR2B antagonists with significantly different biaryl templates. These new advances have raised hope, for potential success of the NR2B antagonists as new therapeutic agents, for the treatment of several pathophysiological indications.
Keywords: nr2b antagonists, acyclic amines, piperidines, phenyl piperidines, benzoxazolone, parkinsons disease
Current Pharmaceutical Design
Title: NR2B Selective NMDA Receptor Antagonists
Volume: 8 Issue: 10
Author(s): Sham S. Nikam and Leonard T. Meltzer
Affiliation:
Keywords: nr2b antagonists, acyclic amines, piperidines, phenyl piperidines, benzoxazolone, parkinsons disease
Abstract: NR2B antagonists have received considerable attention in recent years. In this class of excitatory amino acid receptor antagonists NR2B antagonists have shown efficacy in neuroprotection, anti-hyperalgesic and anti-Parkinson animal models. Several groups are involved in developing these compounds as therapeutic agents and evaluating newer therapeutic targets for these agents. Until recently benzylpiperidine and phenylpiperidine templates, which were based on the structures of Ifenprodil and Eliprodil, formed the basis of most SAR in this area. A few chemical leads in this class such as CP-101,606, Ro25,6981 and PD0196860 have been identified as possible development leads which have generated significant interest in this area. In addition to the efforts of Pfizer (Parke-Davis), Roche and E.Merck, several other industrial and academic research groups have continued to work in the NR2B area and recently Merck and Roche have reported new chemical leads as NR2B antagonists with significantly different biaryl templates. These new advances have raised hope, for potential success of the NR2B antagonists as new therapeutic agents, for the treatment of several pathophysiological indications.
Export Options
About this article
Cite this article as:
Nikam S. Sham and Meltzer T. Leonard, NR2B Selective NMDA Receptor Antagonists, Current Pharmaceutical Design 2002; 8 (10) . https://dx.doi.org/10.2174/1381612024607072
DOI https://dx.doi.org/10.2174/1381612024607072 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine
Current Cancer Drug Targets Neuroanatomical and Neurophysiological Abnormalities in the Neural Correlates of Face Processing in Schizophrenia
Current Psychiatry Reviews Hypersensitivity Reactions from Excipients in Systemic Glucocorticoid Formulations
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Towards an Integrated Clinical Psychobiology of Alcoholism
Current Psychiatry Reviews Cationicity and Hydrophobicity Enhance the Cytotoxic Potency of Phoratoxin C Anticancer Peptide Analogues against Triple Negative Breast Cancer Cells
Current Bioactive Compounds Phasic Dopamine Release in Appetitive Behaviors and Drug Addiction
Current Drug Abuse Reviews L-Carnitine - Metabolic Functions and Meaning in Humans Life
Current Drug Metabolism Author Index To Volume 3
Current Alzheimer Research Functional Connectivity Hubs Could Serve as a Potential Biomarker in Alzheimer’s Disease: A Reproducible Study
Current Alzheimer Research Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Biosynthetic and Metabolic Alterations in Cancer Growth
Current Angiogenesis (Discontinued) Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Biomedical Applications of Carbon Nanotubes: A Critical Review
Current Drug Delivery Alzheimers Disease: An Overview of Current and Emerging Therapeutic Strategies
Current Topics in Medicinal Chemistry Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers
Current Psychiatry Reviews Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy
Current Gene Therapy Relative Position of the Fingers Affects Length Perception While Grasping Objects
Neuroscience and Biomedical Engineering (Discontinued) Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease
Current Drug Targets Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design Cannabidiol Adverse Effects and Toxicity
Current Neuropharmacology